# Neuroscience of classic psychedelics

The study of serotonergic psychedelics has transitioned from the peripheries of psychopharmacology to the forefront of translational neuroscience. Following a decades-long regulatory moratorium, the biomedical evaluation of classic psychedelics—namely psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), and mescaline—has resumed, driven by clinical trials demonstrating robust efficacy in treating major depressive disorder, post-traumatic stress disorder, and substance use disorders [cite: 1, 2]. Beyond clinical outcomes, neuroscientific inquiry focuses on the mechanisms through which these molecules systematically alter hierarchical brain dynamics, induce neuroplasticity, and reshape subjective consciousness.

Recent multi-modal investigations combining cellular electrophysiology, wide-field optical imaging, and high-resolution functional magnetic resonance imaging (fMRI) have fundamentally revised historical models of psychedelic action [cite: 3, 4]. The contemporary consensus indicates that psychedelics are not exclusively cell-surface serotonin 2A (5-HT2A) receptor agonists. Rather, they act as complex neuromodulators targeting intracellular receptor pools, driving enduring functional electrophysiological plasticity that outlasts structural synaptic growth, and inducing profound state-changes in global network connectivity [cite: 4, 5, 6]. This report comprehensively analyzes the molecular, cellular, and systems-level neuroscience of classical psychedelics, while addressing novel methodological confounders related to neurovascular coupling.

## Receptor Pharmacology and Binding Affinities

The foundational hypothesis of psychedelic neuroscience posits that acute subjective effects are primarily mediated by agonism or partial agonism at the 5-HT2A receptor [cite: 7, 8, 9]. This G protein-coupled receptor (GPCR) is densely expressed on the apical dendrites of Layer V pyramidal neurons in the prefrontal cortex, posterior cingulate cortex, and claustrum [cite: 7, 10]. The necessity of 5-HT2A activation is well-documented; pretreatment with the highly selective 5-HT2A antagonist ketanserin reliably abolishes the core subjective effects of psychedelics in human subjects and blocks the head-twitch response in murine models [cite: 11, 12]. However, focusing exclusively on 5-HT2A obscures the complex polypharmacology of these substances.

### Comprehensive GPCR and Kinase Profiling

Psychedelics exhibit broad and highly variable binding profiles. A 2025 systematic pharmacological study profiled 41 classical psychedelics against a massive panel of 318 human GPCRs and over 450 human kinases [cite: 13, 14]. The data revealed that classical psychedelics act potently across an unexpectedly wide array of serotonergic, dopaminergic, and adrenergic receptor subtypes [cite: 13, 14]. 

Ergolines, such as LSD, display highly promiscuous receptor binding. LSD interacts with high affinity not only at 5-HT1A, 5-HT2C, and 5-HT7 receptors but also at dopamine D1 through D4 receptors and alpha-2 adrenergic sites [cite: 15, 16]. Tryptamines, including DMT and psilocin (the pharmacologically active metabolite of the prodrug psilocybin), exhibit a narrower pharmacological spectrum, primarily targeting serotonergic networks and trace amine-associated receptors [cite: 15, 16]. Phenethylamines, such as mescaline, are highly selective for 5-HT2A and 5-HT2C receptors with negligible dopaminergic affinity [cite: 15, 17].

**Table 1: Comparative Binding Affinities ($K_i$ in nM) of Classic Psychedelics Across Receptor Subtypes**

| Receptor Target | Psilocybin | Psilocin | LSD | DMT | 5-MeO-DMT |
| :--- | :--- | :--- | :--- | :--- | :--- |
| **5-HT1A** | >10,000 | 567.4 | 1.1 | 119.5 | 60 - 200* |
| **5-HT2A** | >10,000 | 107.2 | 3.5 | 75.3 | 200* |
| **5-HT2C** | >10,000 | 97.3 | 23.6 | ~100 | ~100* |
| **Dopamine D1** | >10,000 | >10,000 | 27.0 | >10,000 | >10,000 |
| **Alpha-1 Adrenergic** | >10,000 | >10,000 | 670* | >10,000 | >10,000 |

*Data derived from multi-receptor binding assays. Lower $K_i$ values denote stronger binding affinity. The table highlights the pharmacological inertness of psilocybin prior to hepatic dephosphorylation into psilocin, and the exceptionally high, pan-receptor potency of LSD [cite: 9, 15, 16, 18]. Asterisks denote values aggregated from specific animal models or varied radioligand contexts.*

### Dose Equivalence and Physiological Divergence

The diverse binding profiles of these compounds result in distinct physiological trajectories, despite generating remarkably similar states of altered consciousness. Controlled head-to-head clinical trials conducted by the Liechti Lab at the University Hospital Basel compared psychoactive-equivalent doses of LSD (100–200 µg), psilocybin (15–30 mg), and mescaline (300–500 mg) [cite: 19, 20]. 

Phenomenological assessments, including the Mystical Experience Questionnaire and ego dissolution inventories, indicated that the acute subjective experiences produced by these three distinct chemical classes are virtually indistinguishable at equivalent doses [cite: 19, 20]. However, systemic physiological effects diverged in a manner consistent with their extended receptor profiles. LSD induced sustained increases in heart rate and circulating oxytocin, reflecting its dopaminergic and adrenergic agonism [cite: 19, 20]. Conversely, psilocybin drove more pronounced elevations in diastolic blood pressure without significant alterations in oxytocin [cite: 19, 20]. Effect duration also scaled precisely with pharmacokinetics: psilocybin effects dissipated within 4.9 hours, LSD averaged 8.2 hours, and mescaline persisted for 11.1 hours due to prolonged plasma elimination half-lives [cite: 20].

## Intracellular Receptors and Molecular Signaling

Pharmacological models have historically presumed that classical psychedelics act upon receptors located on the external surface of the cellular membrane. Recent investigations into molecular localization have fundamentally overturned this assumption.

### Lipophilicity and Membrane Permeability

Serotonin is a highly polar, hydrophilic molecule that cannot cross the neuronal lipid bilayer, strictly confining its action to cell-surface receptors [cite: 5]. In contrast, classical psychedelics are highly lipophilic molecules. This chemical property allows them to passively diffuse across neuronal membranes and engage a distinct, intracellular pool of 5-HT2A receptors located on the endoplasmic reticulum and Golgi apparatus [cite: 5, 17].

Activation of these intracellular populations triggers entirely different signal transduction cascades than surface activation. Intracellular 5-HT2A receptors associate with cytoskeletal microtubule-associated proteins (such as MAP1A), positioning them to directly modulate neuronal cytoarchitecture and dendritic reorganization [cite: 5]. This spatial selectivity represents a critical mechanism for neuroplasticity. Membrane-impermeable serotonin analogs do not trigger cortical growth, whereas membrane-permeable psychedelics do, explaining why conventional selective serotonin reuptake inhibitors (SSRIs) fail to produce the rapid psychoplastogenic effects observed with psilocybin and DMT [cite: 5, 17].

## Neuroplasticity and Cellular Alterations

The therapeutic durability of psychedelics is widely attributed to their capacity to induce rapid neural plasticity in brain regions damaged by chronic stress, trauma, and depression. Initially, this plasticity was characterized strictly in morphological terms.

### Acute Structural Plasticity: Dendritogenesis and Spinogenesis

Preclinical studies demonstrate that single exposures to classical psychedelics (including LSD, DMT, and DOI) induce rapid structural neuroplasticity. Within 24 hours of administration, cultured cortical neurons exhibit significantly increased dendritic arborization, elevated spine density, and larger spine head sizes [cite: 12, 21, 22]. 

This structural growth is mediated by complex intracellular signaling networks rather than the 5-HT2A receptor acting in isolation. Psychedelic agonism stimulates the extracellular release of Brain-Derived Neurotrophic Factor (BDNF) [cite: 21, 23]. The subsequent binding of BDNF to the tropomyosin receptor kinase B (TrkB) receptor activates the mammalian target of rapamycin (mTOR) signaling pathway, which synthesizes the proteins necessary for new synapse formation [cite: 12, 24]. The necessity of this cascade has been empirically validated: pretreatment with rapamycin (an mTOR inhibitor), ANA-12 (a TrkB antagonist), or ketanserin completely aborts psychedelic-induced neuritogenesis [cite: 12, 22]. Notably, psychedelics may also bind allosterically to the TrkB receptor, stabilizing it to enhance the efficacy of endogenous BDNF [cite: 7].

### The Shift to Enduring Functional Plasticity

While structural plasticity provides an attractive mechanism for rapid antidepressant effects, the physical longevity of these new synapses has been questioned. In a paradigm-shifting 2025 study published in *Neuropsychopharmacology*, Kramer et al. evaluated the long-term cellular architecture of rodent brains months after a single administration of psilocybin [cite: 4, 25]. 

The researchers discovered that the initial surge in structural plasticity is highly transient. By the three-month mark, dendritic spine density, synaptic architecture, and local gene expression in the medial prefrontal cortex had entirely reverted to baseline control levels [cite: 4, 25, 26]. Despite the disappearance of the physical scaffolding, the behavioral antidepressant effects (measured via the forced swim test) remained robustly intact [cite: 4, 25]. 

Subsequent whole-cell patch-clamp electrophysiology revealed the actual mechanism sustaining these behavioral changes: enduring functional plasticity. Layer V excitatory pyramidal neurons exhibited permanent, significant alterations in their resting membrane potentials, baseline firing rates, and overall synaptic excitability [cite: 4, 25, 26]. This indicates that psychedelics achieve their months-long therapeutic effects not by maintaining new physical connections, but by rewriting the long-term electrophysiological transmission rules of the existing neural circuitry [cite: 4, 26].

## Macroscopic Brain Network Dynamics

At the systems level, normal waking consciousness is maintained by distinct, modular neural networks operating with high internal synchrony. Psychedelics temporarily abolish this modularity, inducing a state of global neural desegregation.

### The Global Meta-Analysis of Functional Connectivity

In 2024 and 2026, researchers published the results of an international consortium study in *Nature Medicine*, constituting the largest mega-analysis of psychedelic functional neuroimaging ever conducted. By aggregating 11 independent datasets containing over 500 brain imaging sessions from 267 participants across five countries, the researchers established a definitive "neural fingerprint" common to psilocybin, LSD, mescaline, DMT, and ayahuasca [cite: 1, 2, 27].

The meta-analysis isolated two universal shifts in resting-state functional connectivity across all tested compounds:
1. **Intra-network Desegregation:** The synchronized, highly structured communication *within* canonical brain networks systematically breaks down, rendering individual networks less rigid and less cohesive [cite: 1, 6].
2. **Inter-network Hyperconnectivity:** Concurrently, global cross-talk radically increases *between* networks that normally operate independently. The most pronounced connectivity increases occurred between high-level executive systems (the frontoparietal and default mode networks) and lower-level sensory regions (the visual and somatomotor networks) [cite: 2, 27].

This functional flattening of the brain's hierarchy enables raw sensory inputs to interface directly with higher-order cognitive processing centers, providing a direct biological correlate for the synesthesia, geometric hallucinations, and novel cognitive insights reported during acute psychedelic states [cite: 2, 27].

### Reevaluating the Default Mode Network (DMN)

Historically, psychedelic neuroimaging focused heavily on the Default Mode Network (DMN), a distributed circuit including the medial prefrontal cortex and posterior cingulate cortex that manages self-referential thought and autobiographical memory [cite: 28, 29, 30]. Early correlations between DMN disintegration and the subjective experience of "ego dissolution" led to widespread claims that the DMN was the biological seat of the ego, and that psychedelics functioned simply by disabling this network [cite: 29, 30, 31].

Current neuroscience regards this narrative as a severe oversimplification. Recent analyses highlight that numerous non-psychedelic substances, including amphetamines and alcohol, significantly decrease DMN connectivity; however, these substances frequently increase egotistical behavior, directly contradicting the DMN-ego hypothesis [cite: 32]. Furthermore, the DMN is critically involved in abstract social cognition and empathy. The suppression of the DMN under psychedelics is now understood not merely as the deletion of the "self," but as a blurring of the computational boundaries between the self and the external environment, facilitating the profound sense of interpersonal and ecological connectedness reported in clinical trials [cite: 28, 32].

## Methodological Confounders: The Neurovascular Disconnect

The foundation of human psychedelic neuroimaging relies heavily on Blood Oxygen Level-Dependent (BOLD) fMRI. BOLD signals capture changes in blood flow and oxygenation, relying on the assumption of neurovascular coupling—the principle that local vascular dilation perfectly mirrors local neuronal firing [cite: 3, 33]. A critical 2025 study in *Nature Neuroscience* by Padawer-Curry et al. revealed that classical psychedelics systematically violate this assumption.

Because serotonin receptors are located not only on neurons but also on vascular smooth muscle cells and astrocytes, psychedelics exert direct, independent control over cerebral vasculature [cite: 3]. Using wide-field optical imaging alongside 5-HT2A agonists in murine models, researchers demonstrated that psychedelics completely decouple neuronal activity from hemodynamic activity. The drug induces significant vasodilation or vasoconstriction depending on the brain region, regardless of whether the underlying neurons are firing [cite: 3, 34, 35]. 

Consequently, the sweeping functional connectivity changes mapped over the past decade via fMRI are partially confounded by the drug's action on blood vessels [cite: 33, 36]. While fMRI remains a vital tool, researchers must now apply advanced calibrated models to separate true neural desynchronization from chemically induced vascular artifacts, particularly when assessing DMN connectivity [cite: 3, 36].

## Theoretical Models of Brain Action

To synthesize molecular pharmacology with macroscopic network alterations, computational neuroscientists have advanced three dominant, competing circuit-level models of psychedelic action.

[image delta #1, 0 bytes]





### Relaxed Beliefs Under Psychedelics (REBUS)

The REBUS framework, developed by Carhart-Harris and Friston, interprets psychedelic action through the lens of hierarchical predictive coding and the Free-Energy Principle [cite: 8, 37, 38]. The brain operates as an inference engine, continuously generating top-down expectations ("priors") to interpret incoming, bottom-up sensory data [cite: 39]. In psychiatric conditions such as depression or addiction, these high-level priors become pathologically rigid and overweighted, severely restricting cognitive flexibility [cite: 8, 38].

REBUS asserts that 5-HT2A agonism flattens this hierarchical architecture by drastically reducing the "precision weighting" (confidence) of high-level priors [cite: 8, 39]. This relaxation increases overall brain entropy, permitting unfiltered bottom-up sensory and limbic information to flood the cortex. A 2025 causal evaluation of the REBUS model in mice performing perceptual decision-making tasks confirmed these computational mechanics [cite: 40]. Under the influence of psilocybin, cellular-resolution calcium imaging of the orbitofrontal cortex revealed a reduction in neuronal population correlations—the precise signature of weakened top-down priors—forcing the animals to rely heavily on bottom-up sensory evidence rather than established behavioral routines [cite: 40]. 

### The Cortico-Striato-Thalamo-Cortical (CSTC) Loops

The CSTC model represents a more strictly structural approach, positing that sensory gating is governed by feedback loops connecting the cortex, striatum, and thalamus [cite: 10, 37, 41]. The thalamus normally acts as an informational filter, restricting the volume of raw sensory data reaching consciousness. The CSTC model argues that psychedelic activation of the medial prefrontal cortex heavily modulates striatal output, effectively releasing the inhibitory brakes on the thalamus [cite: 37, 42, 43]. This disinhibition inundates the sensory cortices with unprocessed stimuli, directly driving visual distortions and sensorimotor alterations [cite: 37, 41].

### The Cortico-Claustro-Cortical (CCC) Circuit

The CCC framework centralizes the role of the claustrum, a subcortical sheet of gray matter exhibiting an exceptionally high density of 5-HT2A receptors [cite: 10, 37, 41]. The claustrum acts as a global pacemaker, entraining distinct cortical regions into highly synchronized resting-state networks [cite: 10, 44, 45]. 

The CCC model proposes that psychedelics aggressively decouple the claustrum from the prefrontal cortex [cite: 37, 44]. Without claustral entrainment, canonical networks immediately desynchronize. In late 2025, dynamic causal modeling of resting-state fMRI provided the first in vivo confirmation that psilocybin disrupts claustral effective connectivity [cite: 45]. Concurrently, electrophysiological studies on murine models revealed that 5-HT2A agonists reverse synaptic plasticity rules in claustro-cortical circuits—flipping baseline long-term depression (LTD) to long-term potentiation (LTP)—providing a direct synaptic mechanism for the disruption of global network states [cite: 46].

## Dimethyltryptamine and Endogenous Neuroprotection

While psilocybin and LSD dominate therapeutic discourse, N,N-dimethyltryptamine (DMT) functions through unique neurobiological channels. DMT is the only classic psychedelic endogenously synthesized in the mammalian central nervous system, where it exists at concentrations comparable to serotonin and dopamine [cite: 47, 48].

### The Sigma-1 Receptor Interface

DMT possesses a dual pharmacological identity. In addition to 5-HT2A agonism, DMT functions as an endogenous ligand for the Sigma-1 receptor [cite: 47, 48]. Sigma-1 is an intracellular chaperone protein located at the mitochondria-associated endoplasmic reticulum membrane, where it regulates cellular survival, oxidative stress, and the misfolding of proteins [cite: 47, 48]. 

### Stroke Models and Neuroimmune Regulation

Recent data indicate that DMT's interaction with the Sigma-1 receptor imparts powerful, non-hallucinogenic neuroprotective properties. A 2025 study by the HUN-REN Biological Research Centre utilized transient middle cerebral artery occlusion (ischemic stroke) in rat models to test DMT's neurorestorative capacity [cite: 49, 50]. 

Administration of DMT resulted in significant reductions in both stroke infarct volume and cerebral edema [cite: 49, 50]. Crucially, DMT restored tight junction integrity, physically repairing the damaged blood-brain barrier [cite: 49, 50]. Molecular analyses confirmed that these benefits were driven via the Sigma-1 receptor, which suppressed the release of pro-inflammatory cytokines and heavily restricted the activation of destructive microglial cells [cite: 49, 50]. These findings elevate endogenous DMT from a mere hallucinogen to a potent neuroimmune regulator with substantial adjuvant potential for acute neurological injury [cite: 47, 49].

## Global Clinical Infrastructure and Ritual Context

The acceleration of psychedelic neuroscience has been heavily supported by global research ecosystems, particularly in South America, where the legal status of the DMT-containing brew ayahuasca has facilitated robust clinical investigation [cite: 51, 52]. Research institutions in Brazil, notably the Brain Institute at the Federal University of Rio Grande do Norte, have pioneered trials mapping ayahuasca’s rapid antidepressant effects and its modulation of inflammatory biomarkers [cite: 52, 53, 54].

In January 2026, researchers published a landmark randomized controlled trial evaluating ayahuasca in 429 participants—the largest psychedelic clinical trial to date [cite: 51]. The trial utilized a unique methodology to unbundle the pharmacological effects of the psychedelic from the psychological impact of the group ritual setting [cite: 51]. The data revealed that participation in the ritual alone (via placebo) occasionally induced a "mystical-type experience," which correlated with mild improvements in well-being [cite: 51]. However, the administration of the active DMT compound within the ritual setting maximized the duration and magnitude of psychological relief, confirming that the optimal therapeutic outcome relies on the synergistic interaction between intense neuropharmacological disruption and highly structured psychosocial contexts [cite: 51].

## Conclusion

The neuroscience of classic psychedelics has evolved dramatically from mid-century paradigms that viewed these compounds merely as simple surface-level serotonin agonists or psychotomimetics. Contemporary research outlines a highly sophisticated class of neuromodulators that interface with the brain across every biological scale. From their passive diffusion across lipid bilayers to activate intracellular receptors, to their induction of enduring electrophysiological plasticity that outlasts physical synaptic growth, psychedelics act as profound systemic disruptors. As complex network theories like REBUS and CCC are refined by new data addressing neurovascular confounders and massive receptor profiling, classical psychedelics stand not only as breakthrough interventions for psychiatric illness but as indispensable molecular probes for decoding the architecture of human consciousness.

## Sources
1. [The Transmitter: Psychedelics muddy fMRI results](https://www.thetransmitter.org/psychedelics/psychedelics-muddy-fmri-results-qa-with-adam-bauer-and-jonah-padawer-curry/)
2. [MDPI: Brain State Classification](https://www.mdpi.com/2076-3425/14/9/880)
3. [ResearchGate: What fMRI studies say about psychedelics](https://www.researchgate.net/publication/393687028_What_fMRI_studies_say_about_the_nature_of_the_psychedelic_effect_a_scoping_review)
4. [Neural correlates of the psychedelic state as determined by fMRI](http://behavioralhealth2000.com/wp-content/uploads/2017/05/Neural-correlates-of-the-psychedelic-state-as-determined-by-fMRI-studies-with-psilocybin.pdf)
5. [Frontiers in Physiology: Physiological noise in fMRI data](https://www.frontiersin.org/research-topics/24211/physiological-noise-in-fmri-data-and-brain-resting-state-functional-connectivity/magazine)
6. [PMC: Long-term effects of Ayahuasca](https://pmc.ncbi.nlm.nih.gov/articles/PMC12604547/)
7. [Chacruna: Building a psychedelic research hub in Brazil](https://chacruna.net/building-a-psychedelic-research-hub-in-brazils-public-university-system/)
8. [UBC Economics: Psychedelics RCT](https://economics.ubc.ca/wp-content/uploads/sites/38/2021/07/Psychedelics_RCT.pdf)
9. [McGill: Largest ever study on psychedelics](https://www.mcgill.ca/medhealthsci-research/article/largest-ever-study-psychedelics-could-help-advance-their-use-treating-mental-health)
10. [EurekAlert: Common brain activity pattern across psychedelics](https://www.eurekalert.org/news-releases/1123228)
11. [Brain: Models of psychedelic drug action](https://academic.oup.com/brain/article-abstract/145/2/441/6460325)
12. [Brain PDF: Models of psychedelic drug action](https://academic.oup.com/brain/article-pdf/145/2/441/43390579/awab406.pdf)
13. [ResearchGate: Models of psychedelic drug action](https://www.researchgate.net/publication/357015856_Models_of_psychedelic_drug_action_modulation_of_cortical-subcortical_circuits)
14. [Frontiers in Psychology: Neurobiological aspects](https://www.frontiersin.org/journals/psychology/articles/10.3389/fpsyg.2023.1100058/full)
15. [YouTube: Psychedelic effects on brain circuits](https://www.youtube.com/watch?v=N1CUOKa6aPg)
16. [Google Search: Time in Brazil](https://www.google.com/search?q=time+in+Brazil)
17. [Google Search: Time in Switzerland](https://www.google.com/search?q=time+in+Switzerland)
18. [Frontiers in Psychiatry: Neuroplasticity and psychedelics](https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2021.724606/full)
19. [PMC: Structural neuroplasticity psychedelics](https://pmc.ncbi.nlm.nih.gov/articles/PMC11853016/)
20. [OPEN Foundation: Psilocybin and neuroplasticity](https://open-foundation.org/psilocybin-and-neuroplasticity/)
21. [LSUHSC: Enduring functional plasticity](https://digitalscholar.lsuhsc.edu/sogs_facpubs/434/)
22. [PubMed: Ketamine and serotonergic psychedelics neuritogenesis](https://pubmed.ncbi.nlm.nih.gov/29898390/)
23. [Psychedelic Science: DMN and psychedelics](https://www.psychedelicsci.com/blog/default-mode-network-and-psychedelics-what-science-shows)
24. [Psychedelics Today: Psychedelics and the DMN](https://psychedelicstoday.com/2020/02/04/psychedelics-and-the-default-mode-network/)
25. [Reality Sandwich: Default Mode Network](https://realitysandwich.com/default-mode-network/)
26. [MIND Foundation: Ego dissolution](https://www.mind-foundation.org/blog/ego-dissolution)
27. [PMC: Systematic review DMN modulation](https://pmc.ncbi.nlm.nih.gov/articles/PMC10032309/)
28. [Liechti Lab: Psychoactive Substances](https://biomedizin.unibas.ch/en/research/research-groups/liechti-lab/)
29. [Liechti Lab: Selected Publications](https://biomedizin.unibas.ch/en/research/research-groups/liechti-lab/selected-publications/)
30. [ResearchGate: Matthias E Liechti](https://www.researchgate.net/profile/Matthias-Liechti/2)
31. [University of Basel: Liechti Publications](https://pharma.unibas.ch/en/persons/liechti-matthias-emanuel/publications/)
32. [EurekAlert: Brain entropy and insight](https://www.eurekalert.org/news-releases/1126647)
33. [PMC: Cellular neurobiology of psychedelics](https://pmc.ncbi.nlm.nih.gov/articles/PMC10669348/)
34. [PsyPost: Receptor-mapping study](https://www.psypost.org/neuroscientists-just-rewrote-our-understanding-of-psychedelics-with-a-groundbreaking-receptor-mapping-study/)
35. [Neuroscience News: Psychedelic brain networks](https://neurosciencenews.com/psychedelics-brain-networks-29483/)
36. [OUCI: Psychedelic 5-HT2A receptor agonism](https://ouci.dntb.gov.ua/en/works/4EGd2nAz/)
37. [MDPI: Intracellular 5-HT2A receptors](https://www.mdpi.com/2813-1851/2/4/18)
38. [MIND Foundation: REBUS Model](https://www.mind-foundation.org/blog/rebus)
39. [PMC: REBUS and the anarchic brain](https://pmc.ncbi.nlm.nih.gov/articles/PMC6588209/)
40. [OPEN Foundation: Commentary REBUS](https://open-foundation.org/spotlight-commentary-rebus-and-the-anarchic-brain/)
41. [Medium: The REBUS Model](https://medium.com/@sabourinleandre/the-rebus-model-how-psychedelics-relax-high-level-beliefs-in-the-brain-46a639500e39)
42. [PMC: Classical psychedelics review](https://pmc.ncbi.nlm.nih.gov/articles/PMC11078317/)
43. [University of Bern: Molecular imaging hallucinogens](https://boris-portal.unibe.ch/bitstreams/aae2f1b3-af9f-4fe2-a4db-876d9a732e76/download)
44. [Psychedelic Review: Binding affinity of 5 psychedelics](https://psychedelicreview.com/the-serotonin-receptors-comparing-the-binding-affinity-of-5-psychedelics/)
45. [Reddit: Binding of psilocin to receptors](https://www.reddit.com/r/microdosing/comments/ruki7v/research_data_binding_of_psilocin_dmt_lsd_to_5ht/)
46. [PMC: Serotonergic psychedelics mini-review](https://pmc.ncbi.nlm.nih.gov/articles/PMC10634557/)
47. [The Transmitter: Padawer-Curry Q&A](https://www.thetransmitter.org/psychedelics/psychedelics-muddy-fmri-results-qa-with-adam-bauer-and-jonah-padawer-curry/)
48. [BrainPost: Psychedelics impact neurovascular function](https://www.brainpost.co/weekly-brainpost/2025/10/29/psychedelics-differentially-impact-neuronal-and-vascular-brain-function-via-serotonin-receptors)
49. [WUSTL: Psychedelic 5-HT2A agonism](https://profiles.wustl.edu/en/publications/psychedelic-5-htsub2asub-receptor-agonism-alters-neurovascular-co-4/)
50. [Apple Podcasts: Psychedelics dissociate brain function](https://podcasts.apple.com/lb/podcast/936-psychedelics-dissociate-brain-function/id1827948841?i=1000766948934)
51. [OUCI: Neurovascular coupling literature](https://ouci.dntb.gov.ua/en/works/4EGd2nAz/)
52. [PubMed: Kramer 2025 functional plasticity](https://pubmed.ncbi.nlm.nih.gov/41224969/)
53. [ResearchGate: Kramer functional plasticity](https://www.researchgate.net/publication/397574846_Psychedelics_produce_enduring_behavioral_effects_and_functional_plasticity_through_mechanisms_independent_of_structural_plasticity)
54. [PsyPost: Long-term antidepressant effects](https://www.psypost.org/long-term-antidepressant-effects-of-psilocybin-linked-to-functional-brain-changes/)
55. [Semantic Scholar: Psychedelics Promote Structural plasticity](https://www.semanticscholar.org/paper/Psychedelics-Promote-Structural-and-Functional-Ly-Greb/ff8f30c045c392110cb0b8229c2aae1f515d2084)
56. [eScholarship: Ly et al. 2018](https://escholarship.org/content/qt54887579/qt54887579.pdf)
57. [News-Medical: Common brain activity pattern](https://www.news-medical.net/news/20260408/Study-identifies-a-common-brain-activity-pattern-across-psychedelics.aspx)
58. [Mirage News: Psychedelic study boosts mental health](https://www.miragenews.com/psychedelic-study-may-boost-mental-health-1651229/)
59. [The Guardian: Neural fingerprint of psychedelics](https://www.theguardian.com/science/2026/apr/06/scientists-identify-neural-fingerprint-of-psychedelic-drugs-in-the-brain)
60. [Neuroscience News: Psychedelic brain fingerprint](https://neurosciencenews.com/psychedelic-brain-network-fingerprint-30476/)
61. [Nature Asia: Your brain on psychedelics](https://www.natureasia.com/en/info/press-releases/detail/9295)
62. [Liechti Lab: Comparative studies](https://biomedizin.unibas.ch/en/research/research-groups/liechti-lab/)
63. [PubMed: Double-blind comparison LSD psilocybin](https://pubmed.ncbi.nlm.nih.gov/35217796/)
64. [Technology Networks: Behind the scenes LSD psilocybin comparison](https://www.technologynetworks.com/neuroscience/blog/behind-the-scenes-on-the-first-study-to-compare-the-effects-of-lsd-and-psilocybin-361346)
65. [PubMed: Mescaline LSD psilocybin cross-over](https://pubmed.ncbi.nlm.nih.gov/37231080/)
66. [University of Basel: Friederike Holze Publications](https://biomedizin.unibas.ch/en/persons/friederike-holze/publications/)
67. [Google Scholar: Fernanda Palhano-Fontes](https://scholar.google.com.br/citations?user=WmhroXIAAAAJ&hl=pt-BR)
68. [Remunom: Ayahuasca DMN studies](https://remunom.ojsbr.com/multidisciplinar/article/view/5230)
69. [ResearchGate: Fernanda Palhano-Fontes](https://www.researchgate.net/profile/Fernanda-Palhano-Fontes)
70. [Google Scholar: F. Palhano-Fontes Profile](https://scholar.google.com/citations?user=WmhroXIAAAAJ&hl=en)
71. [PubMed: Ayahuasca for Depression](https://pubmed.ncbi.nlm.nih.gov/34761362/)
72. [Medium: REBUS top-down bottom-up](https://medium.com/@sabourinleandre/the-rebus-model-how-psychedelics-relax-high-level-beliefs-in-the-brain-46a639500e39)
73. [PMC: REBUS hierarchy](https://pmc.ncbi.nlm.nih.gov/articles/PMC6588209/)
74. [Neuroscience of Consciousness: REBUS critique](https://academic.oup.com/nc/article/2020/1/niaa007/5856367)
75. [PubMed: Psychological assumptions REBUS](https://pubmed.ncbi.nlm.nih.gov/39881126/)
76. [PubMed: Rosas 2025](https://pubmed.ncbi.nlm.nih.gov/40696003/)
77. [PMC: DMT Sigma-1 neurobiology](https://pmc.ncbi.nlm.nih.gov/articles/PMC11576444/)
78. [Frontiers in Neuroscience: DMT endogenous hallucinogen](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2016.00423/full)
79. [Neuroscience News: DMT stroke neuroinflammation](https://neurosciencenews.com/dmt-stroke-neuroinflammation-29741/)
80. [MDPI: DMT Alzheimer's model](https://www.mdpi.com/1422-0067/23/5/2514)
81. [PubMed: DMT BBB poststroke](https://pubmed.ncbi.nlm.nih.gov/40802766/)
82. [PMC: Binding affinity Ki values](https://pmc.ncbi.nlm.nih.gov/articles/PMC11078317/)
83. [Psychedelic Review: Table of Ki values](https://psychedelicreview.com/the-serotonin-receptors-comparing-the-binding-affinity-of-5-psychedelics/)
84. [PLOS ONE: Receptor affinity data](https://journals.plos.org/plosone/article/file?type=printable&id=10.1371/journal.pone.0009019)
85. [Wikipedia: Psilocin](https://en.wikipedia.org/wiki/Psilocin)
86. [PMC: PDSP binding assays](https://pmc.ncbi.nlm.nih.gov/articles/PMC2814854/)
87. [Google Search: Time in Brazil](https://www.google.com/search?q=time+in+Brazil)
88. [Google Search: Time in Chile](https://www.google.com/search?q=time+in+Chile)
89. [Google Search: Time in Argentina](https://www.google.com/search?q=time+in+Argentina)
90. [PMC: Circuit models psychedelic action](https://pmc.ncbi.nlm.nih.gov/articles/PMC9014750/)
91. [YouTube: CCC model details](https://www.youtube.com/watch?v=N1CUOKa6aPg)
92. [eNeuro: Psychedelic action in the CLA](https://www.eneuro.org/content/12/10/ENEURO.0047-25.2025)
93. [PubMed: Models of psychedelic drug action](https://pubmed.ncbi.nlm.nih.gov/34897383/)
94. [bioRxiv: In vivo characterization claustral connectivity](https://www.biorxiv.org/content/10.1101/2025.09.07.674759v1.full-text)
95. [Frontiers in Neuroscience: CSTC vs REBUS](https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2025.1606798/full)
96. [PMC: Neuroimaging in clinical trials](https://pmc.ncbi.nlm.nih.gov/articles/PMC10730398/)
97. [bioRxiv: REBUS perceptual decision-making](https://www.biorxiv.org/content/10.1101/2025.09.18.677110.full)
98. [McGill: Largest ever study on psychedelics](https://www.mcgill.ca/medhealthsci-research/article/largest-ever-study-psychedelics-could-help-advance-their-use-treating-mental-health)
99. [Chacruna: Psychedelic science in Brazil](https://chacruna.net/psychedelic-science-in-brazil/)
100. [UBC Economics: Psychedelics RCT](https://economics.ubc.ca/wp-content/uploads/sites/38/2021/07/Psychedelics_RCT.pdf)
101. [Prohibition Partners: Brazil Psychedelic medicines](https://prohibitionpartners.com/2025/12/18/psychedelics-per-country-research-companies-and-market-activity-psych-the-psychedelics-as-medicine-report-3rd-edition/)
102. [SciELO: South American psychedelic renaissance](https://www.scielo.br/j/jbpsiq/a/ZkGccXGhptwR64mv5kwLtrn/?lang=en)

**Sources:**
1. [news-medical.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHSar266qL1KUhFRz2RVKpxig08bL4v47DdgP8XNXOhmL4s60imbVvzgxBcMM73Mq9_mKEk94E9S4zNXo-0_wrg1-IoC8OeugCFXdY7XdF5hd24qiiUEx11t6uNN-5qRcFKI5t9P2XTnkKYVnv28DCf0A9ULx_1MR5tw_6Xup98R5DI36GMMuNNYN_TuCesZ5ydL6o45AZ9bTqZiqkpI4j9QeByilupdrmzxQ==)
2. [theguardian.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGQyPR31CxCEUSqDUK9obFNuVrda34PD-1oqMQwvV6sKPEH2rrbRWAKVRWKXCJer025hllk4UQRo70E3O51ld_kTxrhpoXOnUrn-S25lIheTNis2FeodVxn2E_iy1gDgZlm-gCuYPTolGV7o2uILzMf_lzFjM2FscoOz6jxUrugeQ5Ps2wsrejGnutbrUbKj2VWCJCYOk8HjdiQID2mvpe4yKOHPse5iji2c_4wXVk=)
3. [thetransmitter.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFy02ZpllWtPwqy7jO9Qn-1a-YkQoINsSccF5tdcbvqQGneyVd3VB-yl4shWVJCrTSlbNxpcwDQ7pMENdMCzqHWuEUj9LKvClJ2wZptEOdqtVqXHR19ihRKtfsecirn4HRfItewUe22wphQ9LI5bizT5FKU74T8LqTt5EsI6qFvvxDb7MkoXwXl0eY3Ob8MEkC4v78TVG1heCdlKlDymlB7wwT4wnEO_1qRkZrSaA==)
4. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHtTNtuWxFHyKv2q3KajyNwDd1zQ0RLZNNcZQOzUq4hiAWdZgVruAUBZ5tRMQjl5ksgJlUkage8LF1QoCRbtln0h74xs_w1x2jduFL12Zu8AePR1Fq5G3FGvqYally0Jw==)
5. [mdpi.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH1Ovc-HYiZI_pGdA10WB7cGnI_T3hCRNYOa0SaYnKlN-JCx4pc1khqLxeD2svpNttm-OcDZGlf3CmR4Ht_izZzPzN3cGmjMo3fvJ-jY6BUczt4YQkqp4hQ6umi)
6. [neurosciencenews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHqVFSNsc1aKcZDt-G7XMvbXDuTA4PXuybyejNp1r_iqhEp25XioSw12yi8KtdkBiFyrXaANHmhJToYwE1tQxiTyiEWoSaIwpSrRRK3eD5K1EOemEKhLEEPgTJFEflv_oti2yds3TJ9oLDz7y85uspxoCLpAGr5TpLJiyZVECw2)
7. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEUV746fEDPP7xql-EBarjvBfIIn0U-AIfVzA8N2jMeUKNxbTBsMRcpd978PlF_vH4UW0qWOsbBVNP1Mudy9QhjV2Eqa5YJccS6olLg0spbf82bMy-4piT545iYpbgTe5YXTbTyVFywFg==)
8. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH0X0Auz-1ZeurNUhJybHMjdZ2i0tGHsbvqF1Pow6c45T4MhJZaRpE-bhszip987POEv2mO5fG17dOMtead2aHxyi0rxj4Z4UjSNM80hsiXGSESxP6e1mvuxkTTuzzzwNgxLPXjTChq)
9. [psychedelicreview.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKLNADqbTv_9fEJB5XrPUu9Fdc8_D1aantuJHsUGYU0DUNBbkeBfmB96LJyvu_uWCqCL6byeOzjV5MUasKsIMKSnysQpj9W8A87nS8nZgZ9qCW2weWOx-SZRAoN7_wIbTOdYH4Q4HDjiDzS739r50jDWsCtPAtWyD8PHFtLI4N-nE4lWAmJAk69fb4NbviV-0w5_lSYWVPFlCwvAjh)
10. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFaLVRyTgTpKz_yreCMUtyhki1aGspxg6FtkjBToLwxS6rP0t53f58uvMbbZNeM0ny-ZKhLi6DYQG0niKYOW8RZHEGlZpNsJP8JyqDjY7myDo8OepEFUfjmDQOQMpydmYIluVB-Yc81W9tgjbP3IK_JSuY_-EkZ3Q==)
11. [researchgate.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEXRsRpttCn5XxDXV9jWj3v27i2f_KruEC4SGLl0dV3s3FB53AKWagQmsoJXfExPRJsjDOVxAaRnK0iDjKcdCnkGAKEorMakftf0OUqC1czwb2c0TBkVoYnyGhQspK728-xfEIDWojgVXtyv-m6)
12. [escholarship.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEhsZTvllmo97xNlntT-BFigut1AeU4n1BdF-mK4KoigMHq-8gWGDaLVzxeC-xHxuxLaE9Oty-7Sc3cTiiRD8RItxfcDnlmDZtnMBE2xrJkNI2t7vdgZ1rw-cZ0depsfEcH-bLYRY5qAcZYNlDizAE0)
13. [psypost.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRQ23mi7OIXqz5Ift9R7h0tfK1yCbq9G8Jll8vNTjvAzdM6WwGP4uwh-AeaC9MpE1XoqqhFhqkjOsuzeelA_RvqXQcTl1ULEZ_iyCxA3V60o14QK3r2zxM4l7PanVlIUIG99KlQFA2xsOASBlSP_8ENoktsPeCYIY_81MPfn24zjTGzbYZFjkGTBmiDA9S9qKm6n2KpaLD9HZ4kxLICV4K5xwpeHDPDqEVTz3hVJ3F5DHIC0Qxhk8HWphL)
14. [neurosciencenews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_JQfcjfYPu72o9gQY78F4JoWYo4ppwEzpUJ2sZtXWaug9OYNpaWKxbP8TfrluU1dHtdGSHVcux6gz01fDyIiEH6-XdAAM80Q3t-K4lolejo-s3Xhzj6bTMtucv62ooVnp0Sr7i3DWwGYMFkCawM58abYf4yk=)
15. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHKvPDso0vZljgFeGK-UEp6byrBMZdKvfyCmwTOLxcdcwhcr1WM36ICFc5qn441tHsX0_cus70R-jGs77pb8bjJ3LuDi9eiM6Bi2aa7N-59LwMvdu64rKUXnBS13r5x5pKQGZwwrF6uRg==)
16. [unibe.ch](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGJX9Hp67ScDxG4nIynm7oD9dbJC2gx7kyMuGF5OyI5UKVU1P1JOPGtphDEh8HGUzBUvUillG8A10ZxS0fvxiHlkFShGn7Tsi1cgccZtmvjXuuzruGav6NxykiLOtVOL_aPGyQ4tx4x1vxLprjR9s3IdT9hBiuiuZkDC-vzKjKW8fZB2vHBCVxOZQuMJQ==)
17. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEjQELw1wiKdWWhTQqv8QldCo3KkC7AmIahtkOInHYFq1jIyXli18a6_kTyYnKCcCXXqRi2pJSWyj9YTBUFDgzpKV8mJhcEuJOg1WZEFdDH1LaOpcR-yxD7zom6sJf0loaB79PoMnxE9A==)
18. [plos.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEJf5KyhNFiHMO5_HVAjjnVC_Gm2QwLsNbLVxPsPra4a7BwzslGqwsSp17wGK0iJRh2vXPvKUDgzGtn_lXlswqWcPYw18BgAIP4JAhhsnfB3UPGcsN0hHmDAcXC0Wy40ImtC_4z00Ax9N_95yQ0eaJmOYE6qbsEGOmyW97RMk4qh3wtmissxok99lNh7GVeynB1PBU=)
19. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF_FKCHvDaIHkE6VTuIAq8F6Js8MRzPb70MZ43D5Z50_tRVAKFIKcwu8zm8-Xu_nG1wfY_5UGwR2Jq5G4yqP_sMrsQr3miA0vOJ1sB_CaypiDQrAs-K2n75pVdU99gnSg==)
20. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFxmaxyd-a9gSS1zTvC9GhSZo0hB1vEB8JOu2E9keDsA1A5At92qnm9dEawqNNXiAYdl17_AtKXC_5O3rUb7niZEOOjfzQB1kekf407vp4wEtE-AucB-B0BV_FYzK3xiw==)
21. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFE80XR00NoYVhD8C9J1fq9gYKTmGloeEioQGZhL6Hzmjm37jKAyaELIAOJQ4kytoG3xb1RrY_qJJogt5OUt866fsEcwYWqTCX09dQxC849P-QvsTG1FcN91Am6jbMzyVVASBhojzpMa05CesNu4omEp7G8GaguSbw8IRKPLERgXqPJKVVa90P4mVoACqw=)
22. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFYQga3QMDCrunaNc21okrcMJqhWkGVFixiqck7WFIFxrH6WgrPon3DFwCRMwi4IacWif02GTxA1dRCtV_v4nOqxC0ebNQbwhBsQPSLqWPZif67kG74VUBK9mey6T2kbD3VijbmwCfFSA==)
23. [open-foundation.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHmU69qROCZdRTFPR_D9rG6SWbWi-cJXfk4YZRQui07eWHjXgHl6kGXqLIr0JgKALp3HdBalF7L2hSV4XRrZpzeDRxUPDaP_Z21LOFZzMWHPZwDJ7Oq42c1oPYOAz1sptP5D7KXRbW9MQUZ4f83OdJYIQ==)
24. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHhRDrUgV4krgOwwqdPk0HOP4QhkPqpndteqAtmzFz1t5vklCcndymme8zqxy629Oxxjld0vfmOY9x0XfRIvD2BZbrpTSg4OzdFPNfXjzfMND07cPQn0AW7WRixC5R1NA==)
25. [lsuhsc.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHEonvZ-wCPGkyMN0Uqmi8wImyDLyjQWzNrmRNesBxvd22zi0eSEzoiyd6MWCYRiMAuGtWRlrW-f68reTleDBtqAILOwdeznX7Vpd9VhzsdgwGiWBs74994chj-QA7KVpymnvxp04-TyMo=)
26. [psypost.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQERWpYMwhU3yY_Fcj-g5QDzabjzPpaVe07aNkeVh4I59A2t-Nw5rkzKrnKA3GHafLZpijOSVyme9Ys0uYqc7cNkAIYjjzFKDoQ6N4IqUI3sAjcz4m2Pe7_8K4bUyLgpV7pnwl4i6HlMQAjIxUoYX0mZAKd7VSxNt8m_shf-s1S1GDr0W9OCR9KzgkzUAyed3hNk7F7cVrPHNbqH3XcRGTWT)
27. [natureasia.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGv2K-iapUluJnKjPfdmlUrftMyfXAg6sUlEe3nWMkPAz1vu1r9nkebrjasd9WrjQDDfO_u-hUvdoqMEvTFKyhCrHw3dImGld4_f8C92iYj7t5iqPFtzu7Ndu8c7SuwFBNusKVodOft0AcAOoqESEgK0e0l)
28. [psychedelicsci.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGdg1msKmJ-1KfTSjQblyaYlvf-hanamj5R15cqbyxm1ekTDj7FuMWuai4fUk0Wppv8nOxCxGTS3WA01QEWeHDwmyWhYJkHuA3TD91q0dKya3yEcvvlVnAVDmHNkphvNtGnO53OKHZldHNOySnrHpxDxeiqq3GI_eGKHQJji3-GGn_tOtT8emWUgiQrY2DgcdlYGw==)
29. [psychedelicstoday.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGaKX3pYdY6OedcCVtH5LFkzIroja9_0NFl70d9vNSExesFirG-SaDotwRq8xO1EnlSNMT3P4Tv6MSjXIrFcLIHwNaHCEAPRlj0GNpma9cxF8W3uL_-gU7R_pOXyEZA-pXPPq1RDYyVwlToLcB1avJmtYOT9ggB3-39jkOitAm85GIPjyO4Hq9kjg==)
30. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEaXojLNLaRj4v99Gp6-qt3wfIFlAbndRdp0qbRI-VsGXIN0KFCCk7KATbko__YY2TC3BWuoxfQ47x52mqGMuLGLwkCa27xeWHXA8otyyC_449Kmpc3ZIEnq0LrxHKh0F2B8BiFK9ymRg==)
31. [realitysandwich.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE_IMdd1xlDeI7C5-d8Av5VloVU08zOxz46AO4_vs0XtrVuVqeQwOZKWFIY5pmJE7AuAAHjgCqhjVyZj8W4_LD3_lyAFuwchr1E0Ul9CR7RdSmyetHdR9yvcLbgDYJ_3IcveHB-T3g_)
32. [mind-foundation.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGIU2jzY9oXMudK-Cy7ZIOmRdcsTwVnCMIVHOh50FbahSvvY0Xva4uBhErn2h1C3_E3KV7ylnTj3PeqN19jE8WQXtV3sZBRvrsdy1tfYHCF_ZOWdmuqGKq-5cla1HU5sMBZ9BZ7PNmAi20P)
33. [brainpost.co](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEY7NYNbjg4QZCM457D_GW-PY3WABYiIdd6TGbX4U5jRgLzrDM9hsObT_-bnCbgOSGXA7jFuBPV8mQ20Tz5yXjvwdEoTBSKh6vIp1eD6T6zxo07ct2yEhykdcx_ii23I7PtiRLGiuCJCLXXdy4hp5S_QGnXSuhLhpf3ziCO9fbxbywEf8eyF7-uyOlHpmu46KlDVm6g35no78xbfe1WnP76PBX39wnDV7jSgf-H26UND5lfS91gI-SZsZg39lOmg9GENdarV0XnSoWP8Q==)
34. [wustl.edu](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEnhfAXMcWE-UV8EG53NVmm0o2ERma0_9eDGjxY9dXoHo33aQxyj38CXmfZ8owI4vOOamwAuOWzphZUT325wtxMMwIhYnWDqdhA-CLX2Y3S0ErbnsqYUiJJe7P9XihQLXncSHxJHc41ARE18wC4-CW5hHro7msDJuxKGu8XaMaFCzf_TVyQiubKSyfTCYGilhFUkHYLHK5aV_un5MDTaaqKpc2RcU8=)
35. [dntb.gov.ua](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGLkFI8QmcO8mcka6eX9vPW_igz8WitShmG82xW8SxT4CwCyl6pl2kZVz9ZFieqk0evPe7wR1hhK7TB9547LHaJ5tFpE5l6BZRiv2y93s2nd7cA89DGVdwm9tHzZzCatafV)
36. [apple.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH_er-4Ym63cjRpHX8iyIIW7YQYwMBTKcNkIPmgheExbfTjTviYJpthOyogyJknxr-km2459XOTV7FRxMRSa1IH_OI_7hMw1UPmCzXQNsHyAAakr8m16eFiWAOs0NcjASCmgClDcCZWjTFGXqa8qlFgrK48g6axTzdCDHfe_Em3NqF5UBHQmO7wxPpLnnoHkVNHlZNeBZkqNGrFIo3MRsxqeEFe)
37. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEY-Si2yx1a7v89MoZm-Jjh_OCuEoB7lJ_RLJPMbANmEm3K-sKDxpoJtTOOua1Z7VG2j-5LxpYyX-xaVFiFuJyF4kJWXAec5M1j0330RM-CrCHIYb0lmz-3smu4xCRVknxwfQmy6Mx4HyTiv3fpKV-3Ae14aFhSDNAK1W4dNYdAd98JbQQBNI5qEU1lgnQ0)
38. [mind-foundation.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEYru1F2edRXXuJwUxyFmt9bxIJ0hvhh77pMfJCLjvZlpIu-HbN9RtYtHemA-rBb5fa4yfnizHyUAWxyeXBHuNU5Yft7bzknTeJ1lRdOmD5jBKOjRMzyhh-wILmV86xgUk=)
39. [medium.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHN3JYzMNB9Gdv4gVqnWYS0pVFSdUis5JzgPF5dBOvy_vQj2okOgwl1iw70Wl8rhpOBaCVhVcYUHYIeHN6dLVP1zw6ts9MZKbe1vrNGdBnab3mvBQ6W8eu-Po17pjlLQKDWiuintnKgPhWAJZeZ-4QRD8GQevHlgGDSTN1AYALDZ6CDatUmGLlNNP2VaZkJsNFNVAjK4XLgemv4quucF7Hv54zlu3o1z-dllUxpsw==)
40. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQECbvOr3H-XVrzy38qFA1B7icohvR7ajn6EpbF-UrGqm0Ql-Znq3zM8fVNmFs2I1cQ82g_40F2WZ8w8NQl_EtyqrMN34ahUBkpBYOo08zJXVODPamILhStd3tNNwlcNHPARStKrn45Xfau5jeRHIQ-OqjzkMA==)
41. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7NLk92c8IZWlH8naGz_Q0KcJdmtRqpq3XRYjM0YmMkcXoa_fr-ud7EHjBmTi9Qr75bPiy_MzNj_iI2jqvHIv0j7bvJKKEUqg51-g7YdZhkVriRE86a00xuy_hGH1l3KNZJFF3gwi6)
42. [oup.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEp54nUixeGUJo7SmV5SMJrMd8HD2qE-7-sPir9hRT9i0cOPXYRemShUt-gK47UtfMuaNalek9SPBhhrknYSu298pXJq6Elzp-ooF1TXDbI__T4sm_NBRLqfVjKiOzUukU09fgGu6H6A-ZA1imH2qcs_9YP3iKxrIr9wh2LBpOK)
43. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFcyK8LYVnS2AYVHbK9DrCgg7T-uudk7sZAjejVWvuSLgYfyFnQUd6vEHXSbj2mFKMiiU1bXXdYP-iGCchWrd30d5yr7B2yDWdGRq5vjhdQ1zbOWLuhyIGzYWixSzw6KtZ3v-g2BspuoEwFhTm7XAt9LHjzss2E0eeZ9V9kAVDKFB31MJcV-4rZ_Mh3SYPdt50=)
44. [youtube.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF8clJ1DBjX-aiN0U_LlY6RKJlBSr90LQaY1pq9QaGMihv8WZlm3dnn80Ib2gX1YtW-jVNsvJnaJ0e3exhaAYlt7IXMNKbnd-Ef6CXMnCULzpBQXWmHTvweGcpC-WLHJI6C)
45. [biorxiv.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoBawVN9YstiJhNB6f-uQjeQeWfH0u-4jZniaGKNL6TCpLdOuvtniTgb6xXS7jINOZJR9sXXZuNW_-t7kBP7A0HlLPyT8qMYS6y-zE4dhu5SVSl2zp_rSG1zWN6JXoP7q93EN9b5uzAQvfxKSdm0TGPf-tPbie2SxC-MA=)
46. [eneuro.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFZGQk3_0-NngEgv5upuf2SjBokpPAAMPMjnxEmGjDobEl4UgBdFGgGLUUxMV4RxorO6bCBa_EAiImiRPvH5WtHIf9IHAN8lyXuNZNUqL5MSxAjePIkQU6qIF8yGcOQEddRburJADSMKVztcIYzsg==)
47. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQBEnwk7Q1TQfwA87Zln7dS87fR-ewA3MpcIT_wLD-PiAiKUyNTWYS9pH20JyhyoWXg9vrqg6UbZubCamq19vmXU3p_xbf98oMHERwtzLvWNtxfKdHCaL0OCjt_yP8vwqTCAqceVPh3w==)
48. [frontiersin.org](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFF5sNUgrP6mZrvO18irJimBLtNdhvVXA-KNFKe0pp_zpZkbW-72dmkr-jvL3_TBkKqbKq2q7Sd1Z7ML_Y6vLrvmr_5fh5Ps7suT0y4pBNb4N-phK1qQY7DpSv0kPSWxDp2K9xDv-wvaj1AZUSOKIZOWy3jaaGsoF2x0QonqjMY5dy09KJV2f6uZ6_kRBcd)
49. [neurosciencenews.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFITvvYJQ7V9p9NcjBWOAmp8GA294IppZ1asGR4pzilE5-2Pyhf0zQo-x4kygT7D_0I48imW05cRqnY6vruKEByFRlKzvUsBunLaI_pqBmez6V_AmaevDWIWMRUKUA3A8b2h5nJzhwBoHfrOJq1DxoGI3_RA3AF)
50. [nih.gov](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHBkVGIZrEeZSpdRmYiGgcOsAWagrsLWozmryC0KcHyu-Iu5eldJNc7738V5sneojBrnanra4rZ5dIVgdGZrBld1i8xVfB4F2nQ0bCgnwQH0KuauWGe9XM5Sk4WekEgWA==)
51. [ubc.ca](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHiv0isLtEFF-egm7qskImACqRrK-rGIX6doFhvyZBljp2QEhjFTs_nRhnjTw6HLu2IzuO4mmOyR1BA9EQDkJ_UWhm65_Ff_VndoYiBIezyt6qH865XJn1R5L8ryskUIAx0rg7_ifWo1nJs3zxih1nfuWjcrz5XaaYfY2d9OXVzW37BPkJf5BM=)
52. [chacruna.net](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGKaZ7k-7I8zwb6prIeVYHkfDNz2OXo8Vh4gDCoEZucLgm8ZBAW3jpa4RHCWHDoFk1QK5wFI4q-C4HZE5tf4t9BdjfLoBY9VZG5jyYJdrTUzROqTbVfOD-cDIuokZixTbsKjLuEYcpGRGM=)
53. [google.com.br](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE1lxNiXP9_DYbPuhlAJaVWaMejKdPX78V2t9S8nLonP_9mLcDzQKplgaV5tdqmLJ-_-TCoG2TAaqlROO5epm6xf2C32_ykAYuXaQDzY3JetbqzV19Fx5HgOyRAiniN2jyjnv-AN6SyWFiL6eBtMVTJHogOfCJ9e4o=)
54. [prohibitionpartners.com](https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEH7eEjkcqV_cmxxjHA38EbFNp8Y9zKXLH-w_9DXVkP38ERzM8J2T9c0UYJL88GC1E1vTz0l_xpEox0twUTxdy7hluv6Cfy5fWU4F31tk85iaegGVEc6E6gzkvTbvwpsfTQ_rcar6QN5oIaEBg3ldomVCYtUgWDvgsgNJU23uE1IAZpgkt0VPXFC_vkx4j3LfPqOb6P2PT_IaPWpPF7xE-9uD-G9uELSG-4lRJgArFyEgKhivSgDPx60Kgzz6HO8f6Rlb7DCVd4TvtZ2V_C1en2T9JnaaHP8yU=)